Cabazitaxel in prostate cancer: Stretching a string

The Lancet

Volumn 376, Issue 9747, 2010, Pages 1119-1120

  Dorff, Tanya B ^a   Quinn, David I ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CABAZITAXEL; DOCETAXEL; FLUOROURACIL; IRINOTECAN; MITOXANTRONE; PREDNISONE; SATRAPLATIN; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VITAMIN D; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CANCER VACCINE; ESTRAMUSTINE; SIPULEUCEL T; TAXOID; TISSUE EXTRACT;

CANCER MORTALITY; CANCER SURVIVAL; COLORECTAL CANCER; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SURVEILLANCE PROGRAM; FEBRILE NEUTROPENIA; HUMAN; NEUTROPENIA; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT FAILURE; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; MALE; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; HUMANS; MALE; MITOXANTRONE; PREDNISONE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TAXOIDS; TISSUE EXTRACTS;

EID: 77957665460     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)61510-3     Document Type: Note

References (14)

1. IF Tannock, D Osoba, MR Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764
2. PW Kantoff, S Halabi, M Conaway Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study J Clin Oncol 17 1999 2506 2513
3. DP Petrylak, CM Tangen, MH Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
4. IF Tannock, R de Wit, WR Berry for the TAX 327 Investigators Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
5. CN Sternberg, DP Petrylak, O Sartor Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial J Clin Oncol 27 2009 5431 5438
6. JE Rosenberg, VK Weinberg, WK Kelly Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone Cancer 110 2007 556 563
7. AC Mita, LJ Denis, EK Rowinsky Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors Clin Cancer Res 15 2009 723 730
8. JS de Bono, S Oudard, M Ozguroglu for the TROPIC Investigators Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
9. LB Saltz, JV Cox, C Blanke Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 2000 905 914
10. PW Kantoff, CS Higano, ND Shore for the IMPACT Study Investigators Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
11. DC Danila, MJ Morris, JS de Bono Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer J Clin Oncol 28 2010 1496 1501
12. AH Reid, G Attard, DC Danila Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate J Clin Oncol 28 2010 1489 1495
13. ND James, A Caty, H Payne Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial BJU Int 106 2010 966 973
14. L Fong, SS Kwek, S O'Brien Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF Cancer Res 69 2009 609 615